Skip to Content Skip to Main menu

SEOHAE HOLDINGS CORP .

About us

Home

Company History

  • 2025

    April - Launched the company website.

    March - Moved office to the 26th floor of POSCO Tower in Songdo-dong.

    February - Established a plan for global commercialization of bio/new drug technology at Ajou University.

  • 2024

    August - Received business registration certificate.

Key Executive Experience

  • January 2025 ~

    - EVP(Executive Vice President) at SeoHae Holdings Corporation for Bio/New drug Global Licensing and Business Development

  • December 2024

    - Advisor and EVP(Executive Vice President) at Vastera Co., Ltd., a company developing treatments for PAH(Pulmonary Arterial Hypertension), TNBC(Triple-Negative Breast Cancer), Alzheimer's disease, and dry AMD in charge of Business Development for Global Lincesing and partnering.

  • August 2024

    - Expert in technology commercialization at BTPM for business development and Global Licensing.

  • December 2019

    - Director of IP Management and Business Development for Biotechnology at Gachon University

  • December 2015

    - Director for the Business Development of Biotechnology Commercialization at the KISTA(Korea Intellectual Property and Strategy Agency) under the KIPO(Korean Intellectual Properties Office)

  • April 2010

    - Head of Business Development and Technology Transfer Group for biotechnology commercialization at Dana Patent Law Firm. February 2009: Head of the Technology Commercialization Department at DiT Holdings.

  • November 2007

    - CEO of BioAsia corporation for Business Development of Biotechnology.

  • May 2000

    - Country Manager for Sanofi D. Pasteur French multinational company in Korea and Project Manager for infectious diseases and oncology in the Asia-Pacific region.

  • January 1992:

    - Worked in companies related to bio/healthcare.

Key Executive Activities

  • 2024

    November - Participated in 2024 BioEurope, conducting Global Licensing activities with biotech ventures.

  • 2023

    September - Attended 2023 BioJapan, conducting Global Licensing activities with biotech ventures.

    November - Participated in 2023 BioEurope, executing Global Licensing activities for biotech technologies.

    May - Attended 2023 BioKorea, conducting Global Licensing activities for biotech technologies.

  • 2022

    November - Participated in 2022 BioEurope, conducting Global Licensing activities for the Korea University Medical Center.

    June - Attended the 2022 Biointernational Convention in San Diego, USA, conducting Global Licensing activities for biotech technologies.

    January - Participated in the 2022 JP Morgan Healthcare Conference in San Francisco, USA, engaging in Global Licensing activities for biotech technologies.

  • 2021

    January - Attended the 2021 JP Morgan Healthcare Conference in San Francisco, engaging in Global Licensing activities for biotech technologies.

  • 2020

    June - Participated in the 2020 Biointernational Convention in Philadelphia, USA, conducting Global Licensing activities for biotech technologies.

    May - Attended 2020 BioKorea, conducting Global Licensing activities for biotech technologies.

  • 2019

    June - Participated in the 2019 Biointernational Convention in Boston, USA, engaging in Global Licensing activities for biotech technologies.

  • 2018

    July - Conducted the 2018 Bio-SPC project for the research foundation.

    April - Co-founder of Neuromind Co., Ltd. (CNS Drugs such as Autism Spectrum Disorder, Alzheimer‘s an Parkinson’s).

    January - Co-founder of VasThera Co., Ltd. (Vascular Therapeutics).

    January - Secured a global network at the J.P. Morgan Healthcare Conference.

  • 2017

    September - Co-founder of Entry Bio Co., Ltd. (new drug development and technology commercialization).

    August - Conducted the 2017 Bio-SPC project for the research foundation.

  • 2015

    May - Planned research for discovering and utilizing basic and promising technologies related to new drug technology for the Ministry of Science and ICT.

  • 2014

    August - Developed R&D strategies for dementia drug development for the Ministry of Health and Welfare.

  • 2012

    March - Drafted the 2011 Industrial Convergence Roadmap for U-Health, Ministry of Trade, Industry and Energy.

  • 2011

    July - Signed an MOU with MassBio, a Boston bio-cluster with over 500 member companies in the U.S. bio/pharmaceutical/medical device sectors.

  • 2010

    November - Signed an MOU with MVA, a cluster of over 500 bio/pharmaceutical/medical device companies in Denmark and Sweden.

    October - Developed key areas and detailed strategies through unmet demand and competitiveness analysis for new drug development for the Ministry of Health and Welfare.

  • 2009

    February - Established a strategic partnership with GSK for global technology commercialization of new drug candidates.

Major Performances for Global Licensing and Partnering

The Global Licensing and Technology Transfer-related contracts below are those that are over 10 years old and are acceptable for disclosure. In addition, numerous other contracts have been made over the past 10 years.

2009~2013

  • 2009

    - Agreement for the payment of the Signing Fee in between “Institut Straumann AG and Yonsei University

    - CONFIDENTIAL DISCLOSURE AGREEMENT 2009 in between Trillion, USA and Yonsei Univeresity

    - OPTION AGREEMENT in between GIST and SK Pharmaceuticals, califirnia, USA

    - License Agreement in between “Institut Straumann AG, Switzerland and Yonsei University

    - Confidentialy Agreement by in between Novo Nordisc and Yonsei University

  • 2010

    - CONFIDENTIALITY AGREEMENT in between Immuno Vaccine Technologies and Ewha Woman’s University

    - SECRECY AGREEMENT in between CAPRION PROTEOMICS and Disclosing Party

    - MATERIAL TRANSFER(“MTA“) AND CONFIDENTIAL AGREEMENT in between MILLIPORE CORPORATION,
    USA and Seoul National University

  • 2011

    - Mutual Confidentiality Agreement in between DPharm and GGNT Pharma

    - CONFIDENTIALITY AGREEMENTin between DeBioPharm S.A. and Yonsei University

    - MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT IN Nbetween Cephalon Development Center and GNT Pharma

    - MEMORANDUM OF AGREEMENT(“MOA”) in between Toyota Tsusho Corporation, Japan
    and GNT Pharma

    - Confidential Disclosure Agreement in between Novacta Biosystems Limited and KRICT

  • 2013

    - Non-Disclosure Agreement in between Brickell Biotech Inc., USA and KIST

    - License Term Sheet in between Brickell Biotechnology Inc, USA and KIST